Table 2.
TNA type | Nonfocal | TIA | ||
Exposure groups, n | Exposed | Nonexposed | Exposed | Nonexposed |
372 | 744 | 836 | 1,672 | |
Outcomes, n | ||||
All stroke | 58 | 102 | 171 | 147 |
Ischemic stroke | 29 | 51 | 103 | 88 |
All CHD | 26 | 59 | 68 | 117 |
Acute MI | 22 | 46 | 46 | 93 |
Effect estimates | HR (95% CI) | |||
Model 1 | ||||
All stroke | 1.26 (0.90–1.77) | 2.56 (2.05–3.20) | ||
Ischemic stroke | 1.29 (0.78–2.12) | 2.57 (1.93–3.42) | ||
All CHD | 0.83 (0.51–1.35) | 1.24 (0.92–1.68) | ||
Acute MI | 0.90 (0.52–1.54) | 1.05 (0.73–1.50) | ||
Model 2 | ||||
All stroke | 1.25 (0.89–1.77) | 2.55 (2.04–3.19) | ||
Ischemic stroke | 1.26 (0.76–2.08) | 2.51 (1.88–3.35) | ||
All CHD | 0.80 (0.49–1.31) | 1.22 (0.90–1.65) | ||
Acute MI | 0.89 (0.51–1.56) | 1.04 (0.73–1.50) |
Abbreviations: CHD = coronary heart disease; HR = hazard ratio; MI = myocardial infarction; n = count per group; TNA = transient neurologic attack.
Model 1 adjusted for age at match date, study cohort (RS-I as reference), and maximal level of education (primary education as a reference). Model 2 in addition adjusted for obesity, smoking behavior (never smoking as reference), hypertension, diabetes mellitus, dyslipidemia, prevalent atrial fibrillation, and use of anti-thrombotic medication.